|
201
|
Hu F, Zhao Y, Yu Y, Fang JM, Cui R, Liu ZQ, Guo XL, Xu Q. Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3. Cancer Lett 2017; 416:24-30. [PMID: 29246644 DOI: 10.1016/j.canlet.2017.12.013] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2017] [Revised: 12/08/2017] [Accepted: 12/08/2017] [Indexed: 12/20/2022]
Abstract
Signal transducer and activator of transcription (STAT)3 expression is correlated with neoplasm growth, metastasis, and prognosis; it has also been implicated in the regulation of autophagy, which may in turn contribute to tumor chemoresistance. However, it is unknown whether STAT3 is involved in cancer cell survival in response to chemotherapy. In this study, we show that autophagy is triggered during chemotherapy and that inhibiting autophagy increased chemosensitivity of castration-resistant prostate cancer (CRPC) cells. Meanwhile, docetaxel induced autophagy was inhibited by STAT3 activation, which increased mitochondrial damage and decreased CRPC cell viability. These results suggest that STAT3 contributes to CRPC cell survival and chemoresistance by modulating autophagy.
Collapse
Affiliation(s)
- Fei Hu
- Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, PR China; Tongji University Cancer Center, Shanghai, 200072, PR China; Department of Oncology, Dermatology Hospital, Tongji University, Shanghai, 200443, PR China
| | - Yu Zhao
- Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, PR China; Tongji University Cancer Center, Shanghai, 200072, PR China; Department of Oncology, Dermatology Hospital, Tongji University, Shanghai, 200443, PR China
| | - Yi Yu
- Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, PR China; Tongji University Cancer Center, Shanghai, 200072, PR China; Department of Oncology, Dermatology Hospital, Tongji University, Shanghai, 200443, PR China
| | - Jue-Min Fang
- Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, PR China; Tongji University Cancer Center, Shanghai, 200072, PR China; Department of Oncology, Dermatology Hospital, Tongji University, Shanghai, 200443, PR China
| | - Ran Cui
- Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, PR China; Tongji University Cancer Center, Shanghai, 200072, PR China; Department of Oncology, Dermatology Hospital, Tongji University, Shanghai, 200443, PR China
| | - Zhu-Qing Liu
- Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, PR China; Tongji University Cancer Center, Shanghai, 200072, PR China; Department of Oncology, Dermatology Hospital, Tongji University, Shanghai, 200443, PR China
| | - Xian-Ling Guo
- Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, PR China; Tongji University Cancer Center, Shanghai, 200072, PR China; Department of Oncology, Dermatology Hospital, Tongji University, Shanghai, 200443, PR China.
| | - Qing Xu
- Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, PR China; Tongji University Cancer Center, Shanghai, 200072, PR China; Department of Oncology, Dermatology Hospital, Tongji University, Shanghai, 200443, PR China.
| |
Collapse
|